Terry brings over 20 years of experience in the pharmaceutical and biopharmaceutical industry in his role as the President and Chief Executive Officer of K36.

​

He started his industrial career in process chemistry where he had the opportunity to work on assets at all stages of development during his time at Roche, Wyeth, and Celgene. At Celgene, he transitioned to roles in Business Development, starting with the Alliance Management function where he managed some of the most valuable and complex corporate alliances. From deal close through all phases of the alliance lifecycle, he progressed to Executive Director of Business Development. In his final role with Celgene, Terry led deal evaluation and execution of more than two dozen licensing transactions, collaborations, and private company acquisitions. Prior to joining K36 Therapeutics, Terry served as Chief Business Officer at Dragonfly Therapeutics and Skyhawk Therapeutics, and then Chief Operating Officer at Skyhawk Therapeutics.   

​

Terry holds a B.Sc. (Honors) in Chemistry from Mount Allison University and a Ph.D. in Organic Chemistry from the University of Ottawa.